Cancer Treatment Today

Inhibition of EGFR has been successfully utilized and published for vulvar cancer. In a phase 2 study, erlotinib, an EGFR inhibitor, showed a clinical benefit rate of 67% in women with metastatic vulvar cancer.It also is cited by NCCN..

NCCN Vulvar Cancer VULVA-#, 1 2022

Alexander B. Olawaiye,Mauricio A. Cuello,Linda J. Rogers, Cancer of the vulva: 2021 update, FIGO CANCER REPORT 2021

Horowitz NS, Olawaiye AB, Borger DR, et al. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012;127:141-146.